US Pharma MarketingCity aims to lay foundation for RNAi renaissance with nearly $100M series B
City aims to lay foundation for RNAi renaissance with nearly $100M series B is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Looking to spark an antibody-like revolution for RNA interference medicines, City Therapeutics has landed a nearly $100 million series B to fund a clinical push and power further development of its foundational platform.
Source: FierceBiotech